Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
New York, New York--(Newsfile Corp. - October 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of
Los Angeles, California--(Newsfile Corp. - October 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
01:57pm, Wednesday, 06'th Oct 2021
New York, New York--(Newsfile Corp. - October 6, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences
Cassava Sciences Starts Late-Stage Simufilam Study In Alzheimer's Patients
12:31pm, Wednesday, 06'th Oct 2021
Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an investigational drug for patients with Alzheimer's disease. A second Phase 3 efficacy study of sim
New York, New York--(Newsfile Corp. - October 6, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a sec
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer's Disease
08:30am, Wednesday, 06'th Oct 2021
AUSTIN, Texas, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, announced today it has initiated an initial Phase 3 effi
Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility
06:00am, Wednesday, 06'th Oct 2021
SAVA stock is volatile but worthwhile as its Alzheimer's drug inches closer to commercialization. Risk tolerance is needed, but likely smart The post Cassava Sciences Stock Could Explode as FDA Approv
New York, New York--(Newsfile Corp. - October 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) al
NEW YORK, Oct. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PHG, LIVE and SAVA
07:40pm, Tuesday, 05'th Oct 2021
NEW YORK, NY / ACCESSWIRE / October 5, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies.
Cassava Shareholder Alert
06:28pm, Tuesday, 05'th Oct 2021
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co
New York, New York--(Newsfile Corp. - October 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities o
San Francisco, California--(Newsfile Corp. - October 5, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept
Philadelphia, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is i
New York, New York--(Newsfile Corp. - October 5, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDA
